Astellas: Data show fidaxomicin's efficacy, cost savings

Astellas Pharma Inc. (Tokyo:4503) said a pooled analysis showed that patients receiving fidaxomicin to treat Clostridium difficile infection (CDI) had reduced mortality, recurrence rates and healthcare costs

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE